HIV Treatment and Prevention in Asia (AME)

You will find out if drug resistance is evenly distributed within the region, or whether there are striking differences among countries, and how this reflects on the need for baseline screening. This will be complemented with a comprehensive overview of clinical data on integrase inhibitors-based regimens with regard to their efficacy, tolerability, potential drug-drug interactions, and recommendations in case of HBV or TB co-infection. Alongside this, you will learn about the remaining challenges to scale-up pre-exposure prophylaxis, and how to overcome those by a concerted effort of community and policymakers.

This edition will shed light on the prevalence of HIV drug resistance across Asia and the Pacific region, and its implications on the decision-making process when designing an optimal treatment regimen.
After watching this educational series, you will be able to:

• Evaluate clinical data on integrase inhibitors-based regimens in Asia with regard to their efficacy, tolerability, potential drug-drug interactions, and recommendations in case of pregnancy, HBV or TB co-infection;
• Reflect on the epidemiology of HIV drug resistance across Asia, and understand its implications for clinical and public health implementation;
• Describe progress with implementation of pre-exposure prophylaxis, map remaining challenges, and outline strategies to scale-up.

To obtain your certificate, you have complete all three modules, passed the relevant assessments and answered the evaluation survey.


Module 1 | Use of INSTIs in Asia

Module 2 | HIV Drug Resistance in Asia

Module 3 | Update on PrEP Use in Asia


Duration: approximately 20 minutes per module


You can enhance your learning experience by:

• adding notes to the video modules;
• consulting the accompanying presentation slides;
• sharing your questions and observations with other learners in the discussion board; and
• referring to further literature and other materials provided to you by our experts.

The program is aimed at clinicians from various specialties who occasionally treat HIV patients, such as primary care physicians, family doctors, OBGYN, transgender healthcare clinicians, adolescent medicine professionals, and preventive medicine professionals, as well as public health workers and researchers engaged in HIV related disciplines at varying degrees.